San Diego-based mostly Viking Therapeutics marked alone as a significant competitor within the weight loss drug sector in February just after revealing promising knowledge from the mid-phase demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when given like a weekly injection and in March the comp